Azilect and Raynaud's phenomenon - a phase IV clinical study of FDA data

Summary:

Raynaud's phenomenon is reported only by a few people who take Azilect.

The phase IV clinical study analyzes which people take Azilect and have Raynaud's phenomenon. It is created by eHealthMe based on reports of 7,387 people who have side effects while taking Azilect from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

7,387 people reported to have side effects when taking Azilect.
Among them, 5 people (0.07%) have Raynaud's phenomenon.

What is Azilect?

Azilect has active ingredients of rasagiline mesylate. It is often used in parkinson's disease. eHealthMe is studying from 7,887 Azilect users for its effectiveness, alternative drugs and more.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 1,511 drugs and 933 conditions by eHealthMe.

Number of Azilect and Raynaud's phenomenon reports submitted per year:

Could Azilect cause Raynaud's phenomenon?

Gender of people who have Raynaud's phenomenon when taking Azilect *:

female: 60 %
male: 40 %

Age of people who have Raynaud's phenomenon when taking Azilect *:

Common drugs people take besides Azilect *:

Sinemet: 2 people, 40.00%

Common side effects people have besides Raynaud's phenomenon *:

Weight Increased: 1 person, 20.00%
Peripheral Coldness: 1 person, 20.00%
Oedema Peripheral (superficial swelling): 1 person, 20.00%
Oedema (fluid collection in tissue): 1 person, 20.00%
Nausea (feeling of having an urge to vomit): 1 person, 20.00%
Migraine (headache): 1 person, 20.00%
Itching: 1 person, 20.00%
Insomnia (sleeplessness): 1 person, 20.00%
Constipation: 1 person, 20.00%
Bulimia (eating disorder): 1 person, 20.00%

Common conditions people have *:

Immunodeficiency Common Variable: 1 person, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Azilect and have Raynaud's phenomenon?

Check whether Raynaud's phenomenon is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Hipoglisemi RB, "Rasagiline-Induced Hypoglycemia", , 2016 Jan .

Related studies

How severe was Raynaud's phenomenon and when was it recovered:

Raynaud's phenomenon in Azilect

Expand to all the drugs that have ingredients of rasagiline mesylate:

Raynaud's phenomenon and drugs with ingredients of rasagiline mesylate (5 reports)

Alternative drugs to, pros and cons of Azilect:

Azilect (7,887 reports)

Common Azilect side effects:

Browse all side effects of Azilect:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Raynaud's phenomenon treatments and more:

Raynaud's phenomenon (7,891 reports)

COVID vaccines that are related to Raynaud's phenomenon:

Common drugs associated with Raynaud's phenomenon:

How the study uses the data?

The study uses data from the FDA. It is based on rasagiline mesylate (the active ingredients of Azilect) and Azilect (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.